Gender differences in anticoagulation and antithrombotic therapy

Handbook of Experimental Pharmacology

Volumn 214, Issue , 2012, Pages 523-542

  Rauch, Ursula ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acute coronary syndrome; Antithrombotic therapy; Atrial fibrillation; Bleeding; Coagulation; Estrogens; Gender differences; Platelets; Thromboembolic events

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PRASUGREL; RIVAROXABAN; TICAGRELOR; TIROFIBAN; WARFARIN; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HUMAN; LOW DRUG DOSE; MORBIDITY; PATHOPHYSIOLOGY; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOEMBOLISM; THROMBOSIS; FEMALE; MALE; REVIEW; SEXUAL DEVELOPMENT;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; PLATELET AGGREGATION INHIBITORS; SEX CHARACTERISTICS;

EID: 84868326179     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-30726-3_23     Document Type: Article

References (98)

1. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, Pollack C, Gibler WB, Ohman EM, Peterson ED, CRUSADE Investigators (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 29424:3108-3116
2. Alfredsson J, Swahn E (2010) Management of acute coronary syndromes from a gender perspective. Fundam Clin Pharmacol 24:719-728
3. Alfredsson J, Stenestrand U, Wallentin L, Swahn E (2007) Gender differences in management and outcome in non-ST-elevation acute coronary syndrome. Heart 9311:1357-1362
4. Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, Keltai M, Diaz R, Rangarajan S, Yusuf S, INTERHEART Investigators (2008) Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J 297:932-940
5. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet 3739678:1849-1860
6. Bailey AL, Scantlebury DC, Smyth SS (2009) Thrombosis and antithrombotic therapy in women. Arterioscler Thromb Vasc Biol 29:284-288
7. Bain B, Forester T (1980) A sex difference in the bleeding time. Thromb Haemost 3:131-132
8. Blais N, Pharand C, Lordkipanidzé M, Sia YK, Marhi Y, Diodati JG (2009) Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost 102:404-411
9. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N (2006) Sex differences in platelet reactivity and response to low-dose aspirin therapy. J Am Med Assoc 295:1420-1427
10. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D (1998) Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 98:946-952
11. Berger JS, Bhatt DL, Cannon CP, Chen Z, Jiang L, Jones JB, Mehta SR, Sabatine MS, Steinhubl SR, Topol EJ, Berger PB (2009) The relative efficacy and safety of clopidogrel in women and men a sex-specific collaborative meta-analysis. J Am Coll Cardiol 5421:1935-1945
12. Bonithon-Kopp C, Scarabin PY, Bara L, Castanier M, Jaqueson A, Roger M (1988) Relationship between sex hormones and haemostatic factors in healthy middle-aged men. Atherosclerosis 71:71-76
13. Buchanan MR, Rischke JA, Butt R, Turpie AG, Hirsh J, Rosenfeld J (1983) The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects. Thromb Res 29:125-139
14. Budaj A, Eikelboom JW, Mehta SR, Afzal R, Chrolavicius S, Bassand JP, Fox KA, Wallentin L, Peters RJ, Granger CB, Joyner CD, Yusuf S, OASIS 5 Investigators (2009) Improving clinical outcomes by reducing bleeding in patients with non-ST elevation acute coronary syndromes. Eur Heart J 306:655-661
15. Capodanno D, Angiolillo DJ (2010) Impact of race and gender on antithrombotic therapy. Thromb Haemost 104(3):471-484
16. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 3489038:1329-1339
17. 2+ mobilization. Circ Res 81:885-892
18. Chacko M, Lincoff AM, Wolski KE, Cohen DJ, Bittl JA, Lansky AJ, Tsuchiya Y, Betriu A, Yen MH, Chew DP, Cho L, Topol EJ (2006) Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial. Am Heart J 151:1032.e1-7
19. Chandra NC, Ziegelstein RC, Rogers WJ, Tiefenbrunn AJ, Gore JM, French WJ, Rubison M (1998) Observations of the treatment of women in the United States with myocardial infarction: a report from the National Registry of Myocardial Infarction-I. Arch Intern Med 1589:981-988
20. Chesebro JH, Rauch U, Fuster V, Badimon JJ (1997) Pathogenesis of thrombosis in coronary artery disease. Haemostasis 27:12-18
21. Cho L, Topol EJ, Balog C, Foody JM, Booth JE, Cabot C, Kleiman NS, Tcheng JE, Califf R, Lincoff AM (2000) Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent. J Am Coll Cardiol 36:381-386
22. Cohen M, Antman EM, Gurfinkel EP, Radley D, ESSENCE and TIMI 11B Investigators (2001) ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events) and TIMI (Thrombolysis in Myocardial Infarction) 11B Investigators. Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: treatment benefits in prespecified subgroups. J Thromb Thrombolysis 12:199-206
23. Coller BS, Peerschke EI, Scudder LE, Sullivan CA (1983) A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 72:325-338
24. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S, AVERROES Steering Committee and Investigators (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806-17
25. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
26. Conway DS, Heeringa J, Van Der Kuip DA, Chin BS, Hofman A, Witteman JC, Lip GY (2003) Atrial fibrillation and the prothrombotic state in the elderly: The Rotterdam Study. Stroke 34:413-417
27. Dagres N, Nieuwlaat R, Vardas PE, Andresen D, Lévy S, Cobbe S, Kremastinos DT, Breithardt G, Cokkinos DV, Crijns HJ (2007) Gender related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: A report from the Euro Heart Survey on Atrial Fibrillation. J Am Coll Cardiol 49:572-577
28. De Valk-de Roo GW, Stehouwer CD, Emeis JJ, Nicolaas-Merkus A, Netenlenblos C et al (2000) Unopposed estrogen increases total plasma factor VII, but not active factor VII - A Short term plascebo-controlled study in healthy postmenopausal Women. Thromb Haemost 84:968-972
29. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, van Veldhuisen DJ, ESC Committee for Practice Guidelines (CPG), Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, Document Reviewers, Tendera M, Anker SD, Blanc JJ, Gasparini M, Hoes AW, Israel CW, Kalarus Z, Merkely B, Swedberg K, Camm AJ (2010) 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 31:2677-87
30. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 1148:774-782
31. Eshel-Green T, Berny MA, Conley RB, McCarty OJ (2009) Effect of sex difference on platelet adhesion, spreading and aggregate formation under flow. Thromb Haemost 102:958-965
32. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS (2005) Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 112:1687-1691
33. Faraday N, Goldschmidt-Clermont PJ, Bray PF (1997) Gender differences in platelet GPIIb-IIIa activation. Thromb Haemost 77:748-754
34. Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GY, Bovill EG (1999) Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the Stroke Prevention in Atrial Fibrillation III study. Stroke 30:2547-2553
35. Ferreiro JL, Sibbing D, Angiolillo DJ (2010) Platelet function testing and risk of bleeding complications. Thromb Haemost 103:1128-1135
36. Fernandes LS, Tcheng JE, O'Shea JC, Weiner B, Lorenz TJ, Pacchiana C, Berdan LG, Maresh KJ, Joseph D, Madan M, Mann T, Kilaru R, Hochman JS, Kleiman NS, ESPRIT investigators (2002) Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? Lessons from the ESPRIT study. J Am Coll Cardiol 40:1085-1091
37. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators (1999) Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 3549180:701-707
38. Franzosi MG, Santoro E, De Vita C, Geraci E, Lotto A, Maggioni AP, Mauri F, Rovelli F, Santoro L, Tavazzi L, Tognoni G (1998) Ten-year follow up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto-1 study. The GISSI Investigators. Circulation 9824:2659-2665
39. Gan SC, Beaver SK, Houck PM, MacLehose RF, Lawson HW, Chan L (2000) Treatment of acute myocardial infarction and 30-day mortality among women and men. N Engl J Med 3431:8-15
40. Gordon T, Kannel WB, Hjortland MC, McNamara PM (1978) Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 89:157-161
41. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S (2000) Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 132:689-696
42. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981-92
43. Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A, Woodlief LH, Lee KL, Bovill EG, Simes RJ, Topol EJ (1996) Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 93:870-878
44. Haque SF, Matsubayashi H, Izumi S, Sugi T, Arai T, Kondo A, Makino T (2001) Sex difference in platelet aggregation detected by new aggregometry using light scattering. Endocr J 48:33-41
45. Hart R, Pearce L, McBride R, Rothbart R, Asinger R (1999) Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke 30:1223-1229
46. Herman SM, Robinson JT, McCredie RJ, Adams MR, Boyer MJ, Celermajer DS (1997) Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Rterioscler Thromb Vasc Biol 17:2004-2009
47. Ho PC, Triggs EJ, Bourne DW, Heazlewood VJ (1985) The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites. Br J Clin Pharmacol 19:675-684
48. Hughes M, Lip GY, for the Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care (2007) Risk factors for anticoagulation related bleeding complications in patients with atrial fibrillation: a systematic review. QJM 100:599-607
49. Johnson M, Ramey E, Ramwell PW (1975) Sex and age differences in human platelet aggregation. Nature 253:355-357
50. Jonsdottir LS, Sigfusson N, Gudnason V, Sigvaldason H, Thorgeirsson G (2002) Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study. J Cardiovasc Risk 92:67-76
51. Klein W (1996) Gender differences in clinical trials in coronary heart disease: response to drug therapy. Eur Heart J 1712:1786-1790
52. Kim ES, Menon V (2009) Status of women in cardiovascular clinical trials. Arterioscler Thromb Biol 29:279-283
53. Langer RD, Pradhan AD, Lewis CE, Manson JE, Rossouw JE, Hendrix SL, LaCroix AZ, Ridker PM (2005) Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study. Thromb Haemost 93:1108-1116
54. Lawesson SS, Alfredsson J, Fredrikson M, Swahn E (2012) Time trends in STEMI-improved treatment and outcome but still a gender gap: a prospective observations cohort study from the SWEDEHEART register. BMJ Open 2:e000726
55. Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED (2001) Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2866:708-713
56. Leng XH, Hong SY, Larrucea S, Zhang W, Li TT, Lopez JA, Bray PF (2004) Platelets of female mice are intrinsically more sensitive to agonists than are platelets of males. Arterioscler Thromb Vasc Biol 24:376-381
57. Mahon NG, McKenna CJ, Codd MB, O'Rorke C, McCann HA, Sugrue DD (2000) Gender differences in the management and outcome of acute myocardial infarction in unselected patients in the thrombolytic era. Am J Cardiol 858:921-926
58. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, Wihite HD, Moses JW, King SB 3rd, Ohman EM, Stone GW (2007) Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 4912:1362-1368
59. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women's Health Initiative Investigators (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523-534
60. Mendelsohn ME, Karas RH (1999) The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801-1811
61. Mega JL, Morrow DA, Ostör E, Dorobatu M, Qin J, Antman EM, Braunwald E (2007) Outcomes and optimal antithrombotic therapy in women undergoing fibrinolysis for ST-elevation myocardial infarction. Circulation 11522:2822-2828
62. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW, HORIZONS-AMI Trial Investigators (2009) Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 374:1149-59
63. Meinert CL (1995) The inclusion of women in clinical trials. Science 2695225:795-796
64. Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD (2010) Gender in atrial fibrillation: Ten years later. Gend Med 7:206-217
65. Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G, White K, Goldberg RJ (2003) Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2420:1815-1823
66. O'Brien JR (1951) The bleeding time in normal and abnormal subjects. J Clin Pathol 4:272-285
67. Oldgren J, Johnston N, Siegbahn A (2008) Xa inhibition and coagulation activity - the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. Am Heart J 155:493.e1-8
68. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, Investigators ROCKETAF (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883-91
69. Pengo V, Legnani C, Noventa F, Palareti G, ISCOAT Study Group. (Italian Study on Complications of Oral Anticoagulant Therapy) (2001) Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost 85:418-422
70. Peverill RE, Teede HJ, Smolich JJ, Malan E, Kotsopoulos D, Tipping PG, McGrath BP (2001) Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII. Clin Sci (Lond) 101:93-99
71. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D (2009) Gender differencesin stroke risk of atrial fibrillation patients on oral anticoagulant treatment. Thromb Haemost 101:938-942
72. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. (1988) ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 28607:349-360
73. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH (2001) Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. Ann Intern Med 134:224-38
74. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. J Am Med Assoc 288:321-333
75. Schulman S, Beyth RJ, Kearon C, Levine MN, American College of Chest Physicians (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:257S-298S
76. Schwertz DW, Penckofer S (2001) Sex differences and the effects of sex hormones on hemostasis and vascular reactivity. Heart Lung 30:401-426
77. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W (2007) Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 50:309-315
78. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ, CREDO Investigators (2002) Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 288:2411-2420
79. Stevens RF, Alexander MK (1977) A sex difference in the platelet count. Br J Haematol 37:295-300
80. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon H, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM, Investigators ACUITY (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 35521:2203-2216
81. Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartman F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD, ACUITY Investigators (2007a) Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA 2976:591-602
82. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators (2007b) Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 3699565:907-919
83. Toss H, Wallentin L, Siegbahn A (1999) Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J 137:72-78
84. U.S. Congress Public Law No 103-43. National Institutes of Health Revitalization Act of 1993. June 10, 1993
85. van der Meer FJ, Rosendaal FR, Vadenbroucke JP, Briet E (1993) Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 153:1557-1562
86. Vlotides G, Gaertner R, Angstwurm MW (2007) Modulation of monocytic lipopolysaccharide-indued tissue factor expression and tumor necrosis factor alpha release by estrogen and calcitriol. Hormones 6:52-61
87. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thorsén M (2009a) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 36111:1045-1057
88. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators, Freij A, Thorsén M (2009b) Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 361:1-13
89. Wang TD, Chen WJ, Su SS, Su TC, Chen MF, Liau CS, Lee YT (2001) Increased levels of tissue plasminogen activator antigen and factor VIII activity in nonvalvular atrial fibrillation: relation to predictors of thromboembolism. J Cardiovasc Electrophysiol 12:877-884
90. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, Larson MG, Kannel WB, Benjamin EJ (2003) A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 290:1049-1056
91. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators, (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001-2015
92. Wiviott SD, Cannon CP, Morrow DA, Murphy SA, Gibson CM, McCabe CH, Sabatine MS, Rifai N, Giugliano RP, DiBattiste PM, Demopoulos LA, Antman EM, Braunwald E (2004) Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation 109:580-586
93. Woodfield SL, Lundergan CF, Reiner JS, Thompson MA, Rohrbeck SC, Deychak Y, Smith JO, Burton JR, McCarthy WF, Califf RM, White HD, Weaver WD, Topol EJ, Ross AM (1997) Gender and acute myocardial infarction: is there a different response to thrombolysis? J Am Coll Cardiol 291:35-42
94. Yang X, Alexander KP, Chen AY, Roe MT, Brindis RG, Rao SV, Gibler WB, Ohman EM, Peterson ED, CRUSADE Investigators (2005) The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. J Am Coll Cardiol 46:1490-5
95. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Buday A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 3649438:937-952
96. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina to Prevent Recurrent Events Trail Investiogators, (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 3457:494-502
97. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA (2006a) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354:1464-1476
98. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA, OASIS-6 Trial Group (2006b) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 29513:1519-1530